Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIVENT: 5-FU and LMWH to Prevent PVR in Retinal Detachment
NCT02834559Phase 3Completed
- Sponsor
- University Hospital Cologne
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, low molecular weight heparin calcium in Proliferative Vitreoretinopathy (PVR), sponsored by University Hospital Cologne. Started Oct 2016; status: completed.
02
Drugs
fluorouracillow molecular weight heparin calcium
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT02834559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834559.